Interleukin-17 and interleukin-23: Importance in the pathogenesis of lung impairment in patients with systemic sclerosis

International Journal of Rheumatic Diseases

Volumn 17, Issue 6, 2014, Pages 664-670

  Olewicz Gawlik, Anna ^a   Danczak Pazdrowska, Aleksandra ^a   Kuznar Kaminska, Barbara ^a   Gornowicz Porowska, Justyna ^a   Katulska, Katarzyna ^a   Trzybulska, Dorota ^a   Batura Gabryel, Halina ^a   Silny, Wojciech ^a   Poplawski, Dariusz ^a   Hrycaj, Pawel ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Interleukin 17; Interleukin 21; Interleukin 23; Interstitial lung disease; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN DERIVATIVE;

ADULT; AGED; BLOOD; BODY PLETHYSMOGRAPHY; CASE CONTROL STUDY; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; LUNG; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RADIOGRAPHY; SCLERODERMA, SYSTEMIC; TH17 CELL; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PLETHYSMOGRAPHY, WHOLE BODY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; SCLERODERMA, SYSTEMIC; TH17 CELLS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84933502977     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12290     Document Type: Article

References (33)

1. Awasthi A, Kuchroo VK (2009) Th17 cells: from precursors to players in inflammation and infection. Int Immunol 21, 489-98.
2. Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30, 1201-7.
3. Zhao XF, Pan HF, Yuan H et al. (2010) Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 37, 81-5.
4. Yang L, Anderson DE, Baecher-Allan C et al. (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454, 350-2.
5. Parrish-Novak J, Foster DC, Holly RD, Clegg CH (2002) Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72, 856-63.
6. Terrier B, Geri G, Chaara W et al. (2012) Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 64, 2001-11.
7. Szymanek M, Chodorowska G, Kowal M, Pietrzak A, Miturska R, Krasowska D (2010) Serum soluble Fas levels in patients with systemic sclerosis. Post Dermatol Alergol 5, 406-14.
8. Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H (2010) Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukoc Biol 87, 1019-28.
9. Okamoto Y, Hasegawa M, Matsushita T et al. (2012) Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 64, 3726-35.
10. Radstake TR, van Bon L, Broen J et al. (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE 4, e5903.
11. Kurasawa K, Hirose K, Sano H et al. (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43, 2455-63.
12. Distler JH, Jüngel A, Kowal-Bielecka O et al. (2005) Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 52, 856-64.
13. Komura K, Fujimoto M, Hasegawa M et al. (2008) Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 35, 120-5.
14. Le Pavec J, Launay D, Mathai SC, Hassoun PM, Humbert M (2011) Scleroderma lung disease. Clin Rev Allergy Immunol 40, 104-16.
15. Masi AT, Rodnan GP, Medsger TA et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23, 581-90.
16. Johnson SR, Fransen J, Khanna D et al. (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64, 358-67.
17. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15, 202-5.
18. Clements P, Lachenbruch P, Siebold J et al. (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22, 1281-5.
19. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18, 1520-8.
20. Goh NS, Desai SR, Veeraraghavan S et al. (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177, 1248-54.
21. Murata M, Fujimoto M, Matsushita T et al. (2008) Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 50, 240-2.
22. Nakashima T, Jinnin M, Yamane K et al. (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188, 3573-83.
23. Mathian A, Parizot C, Dorgham K et al. (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71, 1227-34.
24. Truchetet ME, Allanore Y, Montanari E, Chizzolini C, Brembilla NC (2012) Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis 71, 2044-50.
25. Gourh P, Arnett FC, Assassi S et al. (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11, R147.
26. Meloni F, Solari N, Cavagna L et al. (2009) Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 27, 765-72.
27. Rueda B, Broen J, Torres O et al. (2009) The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis 68, 253-6.
28. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278, 1910-4.
29. Croxford AL, Mair F, Becher B (2012) IL-23: one cytokine in control of autoimmunity. Eur J Immunol 42, 2263-73.
30. Diaz-Gallo LM, Simeon CP, Broen JC et al. (2013) Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 72, 1233-8.
31. Castermans K, Tabruyn SP, Zeng R et al. (2008) Angiostatic activity of the antitumor cytokine interleukin-21. Blood 112, 4940-7.
32. Jones JL, Phuah CL, Cox AL et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119, 2052-61.
33. Yang XO, Nurieva R, Martinez GJ et al. (2008) Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44-56.